Discover Disease-Modifying Therapeutics Targeting Misfolded & Oligomeric Proteins in Neurodegenerative Disease & Beyond

This digital summit arrives as the definitive forum for industry professionals and research institutes to shift the drug discovery paradigm to seize the untapped opportunity of protein misfolding targeted therapeutics. Join your peers to:

  • Validate novel druggable targets that underlie protein conformational diseases
  • Improve preclinical predictability of patient derived models
  • Optimize drug pharmacology
  • And accelerate the translation of novel protein misfolding targeted therapeutics into the clinic

With numerous candidates poised to enter the clinic, join the 1st Protein Misfolding Drug Discovery Summit – the only industry and translational focused conference, dedicated to discover and translate disruptive disease-modifying therapeutics targeting misfolding and oligomeric proteins in neurodegenerative disease and beyond.

5 Key Reasons To Attend

Icon 1
Icon 1

Discover the latest understanding of different molecular approaches towards targeting protein misfolding with insights from Prothena & Stanford University

Icon 2
Icon 2

Overcome preclinical challenges for robust translation of protein misfolding targeted therapeutic candidates into the clinic with insights from AbbVie & Eli Lilly

Icon 3
Icon 3

Understand different drug modalities such as immunotherapies, small molecules and peptide-based approaches to accelerate your candidates to clinic with insights from ProMIS Neurosciences, CantaBio Pharmaceuticals & Aelin Therpaeutics

Icon 4
Icon 4

Leverage cross-learnings from clinical case studies to successfully and robustly translate your drug candidates into different clinical indications with insights from Anavex Life Sciences & Lysosomal Therapeutics

Icon 5
Icon 5

Join the momentum to reverse the undruggable nature of misfolded
proteins and aggregates with insights from Yumanity & Wren Therapeutics